The Week in Review: New Investments for a New Year

Beijing announced a 10 billion RMB ($1.5 billion) fund to encourage VC/PE investment in companies sited in Beijing's Zhongguancun Science Park; China Medicine Corp. raised $70 million from a subsidiary of JPMorgan Chase; GL Biochem s signed a definitive reverse merger agreement with Commonwealth Biotech; China Aoxing Pharma (中国奥星药业) completed a Phase II trial of a TCM product for menstrual pain; 3SBio Inc. is seeking SFDA permission to begin a clinical trial of a Western anemia product; Mindray Medical introduced ten new products in 2009, bringing its total count to 70; Shanghai ChemPartner was named to the 2009 Deloitte Technology Fast 50 China list; China Sky One Medical (中国天字一号医药公司) migrated to the NASDAQ Global Select Market; and the MoH reported 648 deaths from H1N1 flu in mainland China during 2009. More details... Stock Symbols: (OTCBB: CHME) (NSDQ: CBTE) (OTCBB: CAXG) (NSDQ: SSRX) (NYSE: MR) (NSDQ: CSKI)